Clinical Trial Update: A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of bevacizumab with bortezomib in relapsed or refractory multiple myeloma has completed enrollment and posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Bortezomib (bortezomib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2012-01-19